Notice of Intent 1

PRE-SOLICITATION

NOTICE OF INTENT TO SOLE SOURCE

Notice Title: Randomized Controlled Trial of a Novel Clinical Decision Support Tool for Individualized Exercise Recommendations in Breast Cancer Survivors Agency: Department of Health and Human Services (HHS), National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD) Contracting Office: NIH Office of Acquisition and Logistics Management (OALM) Notice Type: Pre-solicitation – Notice of Intent to Sole Source Notice ID: 75N94027R00004
NAICS Code: 541715
Product Service Code (PSC): AN12
Response Deadline: 11/25/2026
Description:
The National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD), Division of Intramural Research (DIR), intends to award a sole-source contract to Kaiser Foundation Research Institute, Oakland, California, pursuant to the authority of 41 U.S.C. 3304(a)(1), as implemented by Revolutionary FAR Overhaul (RFO) FAR 6.103-1, Only One Responsible Source and No Other Supplies or Services Will Satisfy Agency Requirements.
The purpose of this acquisition is to conduct a randomized controlled clinical trial evaluating the effectiveness of an existing clinical decision-support tool designed to provide individualized exercise recommendations for breast cancer survivors.
The clinical decision-support tool was developed using a simulation model based on longitudinal clinical and exercise-related data from the Kaiser Permanente Northern California (KPNC) Pathways Study. The underlying model incorporates patient characteristics and clinical information to estimate the potential benefits of different types and amounts of exercise among breast cancer survivors.
NIMHD DIR will provide the existing clinical decision-support tool, study protocol, and initial research instruments. The Contractor will be responsible for implementing the research activities within the required clinical setting, including participant recruitment, study coordination, intervention implementation, data collection, and preparation of research deliverables. The proposed acquisition represents a new phase of research involving prospective evaluation of the tool's effectiveness in clinical practice. The research will include recruitment and enrollment

of eligible breast cancer survivors and clinicians, implementation of the clinical intervention, collection of clinical and patient-reported outcomes, and assessment of the tool's effectiveness in